Acute Toxicity Following Prostate Radiotherapy Linked to Late Toxicity
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Feb. 12, 2025 -- For patients undergoing prostate radiotherapy, acute toxicity is associated with late toxicity and decrement in quality of life, according to a study published online Jan. 30 in The Lancet Oncology.
John Nikitas, M.D., from the University of California, Los Angeles, and colleagues characterized the relationship between acute and late genitourinary and gastrointestinal toxicity among patients receiving conventionally fractionated or moderately hypofractionated prostate radiotherapy in an individual patient data meta-analysis of randomized phase 3 trials. Six trials, with 6,593 patients (4,248 conventionally fractionated; 2,345 moderately hypofractionated), met all eligibility criteria.
Patients were followed for a median of 72 months. The researchers found an association for acute grade 2 or greater genitourinary toxicity with both late grade 2 or greater genitourinary toxicity and decrement at least twice the minimal clinically important difference (MCID) in urinary quality of life (odds ratios, 2.20 and 1.41, respectively). There was also an association for acute grade 2 or greater gastrointestinal toxicity with both late grade 2 or greater gastrointestinal toxicity and decrement at least twice the MCID in bowel quality of life (odds ratios, 2.53 and 1.52, respectively).
"Further prospective studies are needed to evaluate whether strategies that mitigate the risk of acute toxicity lead to reduced rates of late toxicity and whether early interventions to treat acute toxicity impact rates of late toxicity," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted February 2025
Read this next
MedDiet Adherence Seems Beneficial for Benign Prostatic Hyperplasia
THURSDAY, Aug. 14, 2025 -- In patients with benign prostatic hyperplasia (BPH), adherence to the Mediterranean diet (MedDiet) is associated with improved urinary function and...
About One in Six Men With Grade Group 1 Prostate Cancer Has Intermediate-, High-Risk Disease
WEDNESDAY, Aug. 6, 2025 -- A proportion of men with grade group 1 (GG1) prostate cancer have a higher-risk disease than suggested by biopsy, according to a study published online...
Racial Differences Seen in Prostate Cancer Care Quality
WEDNESDAY, July 30, 2025 -- Black men with newly diagnosed prostate cancer have lower odds of overtreatment and confirmatory testing when compared with White men, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.